Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Dec 12, 2019	YANCOPOULOS GEORGE Director, President and CSO Trans History: 617	Director, President and CSO	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	95,295	--	150,000
Dec 13, 2018	YANCOPOULOS GEORGE Director, President and Chief Scientific Trans History: 617	Director, President and Chief Scientific	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	150,000	$16.80	150,000
Dec 14, 2012	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	150,000	--	150,000
Aug 23, 2017	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Other acquisition or disposition	--	--	150,285
Jul 03, 2017	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Bona fide gift	422	--	150,285
Mar 07, 2013	SCHLEIFER LEONARD S Director, President & CEO Trans History: 404	Director, President & CEO	Form 4	Open market or private sale of non-derivative or derivative security	3,534	$175.13	150,404
Apr 03, 2017	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Bona fide gift	547	--	150,707
Jan 03, 2017	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Bona fide gift	571	--	151,254
Dec 20, 2016	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Other acquisition or disposition	--	--	151,825
Oct 03, 2016	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Bona fide gift	531	--	151,825

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media